



## Supplementary File S1. Study vaccine lots

The following lot numbers of the study vaccines and diluents were used: Lyophilized rRSV-G protein 12 $\mu$ g (R201803); CsA diluent 20  $\mu$ g/mL (C201802); Placebo for rRSV-G-protein (R201701K); Placebo for CsA (C201702K). BARS13 dose level was amended from 10  $\mu$ g rRSV-G protein and 10  $\mu$ g Cyclosporine A (CsA) to 9.2  $\mu$ g rRSV-G protein and 10  $\mu$ g CsA. During the dosing of 2 sentinel participants in Cohort 1, it was found that RSV-G was constituted in a lower volume than planned (0.42 rather than 0.5 mL) due to needle dead space was not accounted. By agreement between the Sponsor and the phase I site, it was decided to dose with 9.2  $\mu$ g rRSV-G protein rather than 10  $\mu$ g, while the total volume remained the same by adding extra diluent.



**Figure S1.** The Incidence Rate of TEAEs post first Vaccination by All Cohorts. Abbreviations: Low dose single (LDS), low dose repeat (LDR), high dose single (HDS), and high dose repeat (HDR).



**Figure S2.** The Incidence Rate of TEAEs post second Vaccination by Repeat Dose Recipients. Abbreviations: Low dose repeat (LDR) and high dose repeat (HDR).